SS 08 - GU 2: Bladder and Post-Prostatectomy Radiation

Presentations

• 04:45pm - 04:55pm PT

  Early Detection of Metastatic Progression by Circulating Tumor DNA in Patients Undergoing Bladder-Preserving Trimodality Therapy

  Speaker: Dekuang Zhao, DO, PhD - Moffitt Cancer Center, Tampa
• 04:45pm - 06:00pm PT

  GU 2: Bladder and Post-Prostatectomy Radiation

  Speaker: Leslie Ballas, MD, FASTRO - Cedars Sinai, Los Angeles
• 04:55pm - 05:05pm PT

  Bladder-Specific 15-Gene Transcriptomic Signature Predicts (Chemo)radiation Therapy Response in Muscle-Invasive Bladder Cancer

  Speaker: Xiaohui Li, MD - Department of Medical Oncology, Peking University First Hospital, Beijing
• 05:05pm - 05:15pm PT

  Stereotactic intensity modulated radiotherapy after radical prostatectomy (SCIMITAR): Four-year outcomes of a phase II clinical trial

  Speaker: Jesus Juarez Casillas, MD, MS - UCLA, Los Angeles
• 05:15pm - 05:25pm PT

  Quality of Life after Adjuvant or Salvage Radiotherapy Following Radical Prostatectomy: A Secondary Analysis of the TROG 08.03 RAVES Randomized Controlled Trial

  Speaker: Justin Smith, MBBS - Princess Alexandra Hospital, Woolloongabba
• 05:25pm - 05:35pm PT

  Safety and Efficacy of POstoPerative Ablative RadioTherapy (POPART) for Post-Prostatectomy Biochemical Recurrence

  Speaker: Federica Ferrario, MD - University of Milan Bicocca - School of Medicine and Surgery, Milan
• 05:35pm - 05:45pm PT

  Bladder Only vs. Whole Pelvis Radiotherapy in Trimodality Treatment for Lymph Node Negative Urothelial Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis

  Speaker: Alyssa Anne Granda, MD - Jose R. Reyes Memorial Medical Center, Manila
• 05:45pm - 05:55pm PT

  Discussant

  Speaker: Kent Mouw, MD, PhD - Brigham & Womens Hospital/Dana-Farber Cancer Institute, Boston